Trials / Completed
CompletedNCT02103283
A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.
Detailed description
A Phase 1, Open-Label Safety and Pharmacodynamic Study of RV 001, an Insulin-Like Growth Factor-1 Receptor (IGF-1) Antagonist, Given By IV Infusion in Patients with Diabetic Macular Edema (DME).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teprotumumab | Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2014-04-03
- Last updated
- 2025-06-25
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02103283. Inclusion in this directory is not an endorsement.